Discovery of a new series of PI3K-δ inhibitors from Virtual Screening. (15th June 2021)

• Record Type: Journal Article
• Authors: Fradera, Xavier; Deng, Qiaolin; Achab, Abdelganhi; Garcia, Yudith; Kattar, Solomon D.; McGowan, Meredeth A.; Methot, Joey L.; Wilson, Kevin; Zhou, Hua; Shaffer, Lynsey; Goldenblatt, Peter; Tong, Vincent; Augustin, Martin A; Altman, Michael D.; Lesburg, Charles A.; Shah, Sanjiv; Katz, Jason D.
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 42(2021)
• Publication Date: 2021-06-15
• Subjects: PI3K-δ -- Virtual screening -- Isoindolinone -- Lead Identification; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2021.128046
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Abstract: PI3K-δ mediates key immune cell signaling pathways and is a target of interest for treatment of oncological and immunological disorders. Here we describe the discovery and optimization of a novel series of PI3K-δ selective inhibitors. We first identified hits containing an isoindolinone scaffold using a combined ligand- and receptor-based virtual screening workflow, and then improved potency and selectivity guided by structural data and modeling. Careful optimization of molecular properties led to compounds with improved permeability and pharmacokinetic profile, and high potency in a whole blood assay.